IDEC-2026860



FIGURE 1


A
a
b
c
Viable cells (10^5)
Time (h)
B
EtOH
tRA 1μM
tRA 100nM
tRA 10nM
3
33
22
6
5
25
17
6
PI
Annexin V

FIGURE 2


A
CD86
DR
EtOH
TNF 10 ng/ml
Rol 1μM
Rol 1μM+ TNF 10 ng/ml
Rol 100 nM+ TNF 10 ng/ml
tRA 100 nM
9cRA 100 nM
Cmpd I 100 nM
SR11237 1μM
Cmpd III 1μM
tRA 100 nM+ TNF 10 ng/ml
9cRA 100 nM+ TNF 10 ng/ml
Cmpd I 100 nM + TNF 10 ng/ml
SR11237 1μM+ TNF 10 ng/ml
Cmpd III 1μM+ TNF10 ng/ml
Cmpd I 1μM+ TNF 10 ng/ml
Cmpd VIII 1μM+ TNF 10 ng/ml
B
Rol
tRA
9cRA
I
SR11237
III
% DR/CD86 hi cells
nM retinoids (+10ng/ml TNFα)
C
% DR/CD86 hi cells
TNF
I
III
tRA
9cRA
D
SR11237
E
nM retinoids

FIGURE 3


A
autologous presentation of TT
TT/ SR 100 nM+ T 100 nM+TNFα
TT/ SR 1μM+ T 1μM+TNFα
TT/ tRA 100 nM+TNFα
TT/ SR 1μM+ TNFα
cpm x 10^5
TT/TNFα
TT/tRA 100 nM
TT/SR 1μM
TT/SR 1μM+ T 1μM
no TT
stimulator/effector
4%
16%
B
MLR
SR 1μM+ T 1μM+ TNFα
tRA 1μM+TNFα
TNFα
EtOH
tRA 1μM
SR 1μM+ T 1μM
cpm x 10^5
stimulator/effector
1%
4%
C
IL12 (pg/2.5 105 cells)
tRA
SR
TNF
CD40L

FIGURE 4

FIGURE 5


Preincubation
Medium
Vehicle
tRA
SR11237
Cmpd. II
Cmpd. I
TNFα
− + − + − + − + − + − +
NF-κB
Complexes
Free Probe

FIGURE 6


Immature LC
RAR α/RXR heterodimer
inflammatory stimuli (TNF α)
tRA, 9cRA, Cmpd. I
Cmpd. I/SR11237
agonists
Cmpd. II, Cmpd. VIII
antagonists
(RXR)2 homodimers
or
RXR/other NR heterodimers
SR11237
Cmpd. V
agonists
RAR α/RXR heterodimer
tRA, 9cRA, Cmpd. I
Cmpd. I/SR11237
agonists
Cmpd. VIII
antagonists
apoptosis
immature LC activation (....., ..., ...)